News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
525,128 Results
Type
Article (44701)
Company Profile (121)
Press Release (480306)
Section
Business (144935)
Career Advice (2398)
Deals (27934)
Drug Delivery (118)
Drug Development (67954)
Employer Resources (148)
FDA (15620)
Job Trends (11951)
News (263632)
Policy (29606)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (4)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2288)
Academic (1)
Accelerated approval (3)
Adcomms (29)
Allergies (70)
Alliances (35934)
ALS (76)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (115)
Approvals (15565)
Artificial intelligence (203)
Autoimmune disease (13)
Automation (10)
Bankruptcy (306)
Best Places to Work (9197)
BIOSECURE Act (21)
Biosimilars (99)
Biotechnology (72)
Bladder cancer (53)
Brain cancer (23)
Breast cancer (219)
Cancer (1688)
Cardiovascular disease (141)
Career advice (1999)
Career pathing (31)
CAR-T (126)
Cell therapy (362)
Cervical cancer (14)
Clinical research (54806)
Collaboration (598)
Compensation (392)
Complete response letters (28)
COVID-19 (2583)
CRISPR (36)
C-suite (169)
Cystic fibrosis (91)
Data (1578)
Decentralized trials (2)
Denatured (13)
Depression (44)
Diabetes (222)
Diagnostics (5209)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (86)
Drug pricing (117)
Drug shortages (29)
Duchenne muscular dystrophy (66)
Earnings (57998)
Editorial (34)
Employer branding (20)
Employer resources (135)
Events (76240)
Executive appointments (531)
FDA (16573)
Featured Employer (37)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (534)
Gene editing (86)
Generative AI (21)
Gene therapy (268)
GLP-1 (732)
Government (3846)
Grass and pollen (4)
Guidances (42)
Healthcare (14802)
Huntington's disease (23)
IgA nephropathy (21)
Immunology and inflammation (103)
Indications (21)
Infectious disease (2704)
Inflammatory bowel disease (119)
Inflation Reduction Act (9)
Influenza (41)
Intellectual property (67)
Interviews (448)
IPO (13963)
IRA (48)
Job creations (3155)
Job search strategy (1665)
Kidney cancer (10)
Labor market (20)
Layoffs (484)
Leadership (18)
Legal (6946)
Liver cancer (66)
Lung cancer (242)
Lymphoma (115)
Machine learning (2)
Management (50)
Manufacturing (235)
MASH (59)
Medical device (11148)
Medtech (11151)
Mergers & acquisitions (14346)
Metabolic disorders (619)
Multiple sclerosis (56)
NASH (22)
Neurodegenerative disease (75)
Neuropsychiatric disorders (29)
Neuroscience (1806)
NextGen: Class of 2025 (4984)
Non-profit (3164)
Northern California (2041)
Now hiring (14)
Obesity (351)
Opinion (208)
Ovarian cancer (55)
Pain (70)
Pancreatic cancer (65)
Parkinson's disease (115)
Partnered (13)
Patents (179)
Patient recruitment (73)
Peanut (43)
People (42385)
Pharmaceutical (35)
Pharmacy benefit managers (21)
Phase I (16389)
Phase II (23733)
Phase III (19494)
Pipeline (802)
Podcasts (71)
Policy (122)
Postmarket research (2205)
Preclinical (6581)
Press Release (28)
Prostate cancer (84)
Psychedelics (35)
Radiopharmaceuticals (206)
Rare diseases (344)
Real estate (4254)
Recruiting (59)
Regulatory (20687)
Reports (29)
Research institute (2054)
Resumes & cover letters (401)
Rett syndrome (2)
RNA editing (1)
RSV (41)
Schizophrenia (67)
Series A (108)
Series B (64)
Service/supplier (9)
Sickle cell disease (51)
Southern California (1696)
Special edition (15)
Sponsored (32)
Startups (2741)
State (1)
Stomach cancer (14)
Supply chain (60)
The Weekly (58)
United States (17246)
Vaccines (697)
Venture capitalists (34)
Webinars (11)
Weight loss (269)
Women's health (29)
Worklife (16)
Date
Today (161)
Last 7 days (731)
Last 30 days (2801)
Last 365 days (30881)
2025 (5301)
2024 (31407)
2023 (34982)
2022 (45057)
2021 (48498)
2020 (45511)
2019 (36210)
2018 (27396)
2017 (27804)
2016 (25803)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (671)
Alabama (36)
Alaska (6)
Arizona (153)
Arkansas (9)
Asia (30873)
Australia (5419)
California (4543)
Canada (1312)
China (329)
Colorado (204)
Connecticut (235)
Delaware (106)
Europe (75022)
Florida (685)
Georgia (149)
Hawaii (1)
Idaho (36)
Illinois (377)
India (18)
Indiana (214)
Iowa (7)
Japan (115)
Kansas (79)
Kentucky (13)
Louisiana (5)
Maine (58)
Maryland (727)
Massachusetts (3469)
Michigan (162)
Minnesota (286)
Mississippi (1)
Missouri (60)
Montana (12)
Nebraska (19)
Nevada (47)
New Hampshire (49)
New Jersey (1308)
New Mexico (13)
New York (1269)
North Carolina (795)
North Dakota (6)
Northern California (2041)
Ohio (141)
Oklahoma (7)
Oregon (27)
Pennsylvania (998)
Puerto Rico (6)
Rhode Island (15)
South America (1033)
South Carolina (13)
South Dakota (1)
Southern California (1696)
Tennessee (71)
Texas (640)
Utah (124)
Virginia (101)
Washington D.C. (53)
Washington State (434)
West Virginia (3)
Wisconsin (42)
525,128 Results for "pharmacosmos a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pharmacosmos Group to Acquire G1 Therapeutics
August 7, 2024
·
14 min read
Press Releases
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
September 5, 2024
·
6 min read
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
IPO
‘Valentine’s Day Massacre’: Deerfield Claims Alcon is Blocking Aurion’s IPO
Deerfield Management claims that Alcon Research is seeking a discounted takeover of Aurion Biotech while blocking the startup’s efforts to go public.
February 25, 2025
·
2 min read
·
Tristan Manalac
Deals
Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc.
Pharmacosmos Group today announced the acquisition of AbFero Pharmaceuticals, Inc., a Boston based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload.
November 11, 2021
·
3 min read
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
·
7 min read
·
Heather McKenzie
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
5 min read
·
Heather McKenzie
1 of 52,513
Next
